Results 121 to 130 of about 5,463 (146)

Obinutuzumab

Reactions Weekly, 2023
  +5 more sources

Obinutuzumab

Reactions Weekly, 2017
openaire   +2 more sources

Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzumab for treatment-naive chronic lymphocytic leukaemia (ELEVATE-TN): a randomised, controlled, phase 3 trial

Lancet, The, 2020
Jeff P Sharman, Miklos Egyed, Wojciech Jurczak   +2 more
exaly  

Obinutuzumab

Reactions Weekly, 2018
  +4 more sources

Acalabrutinib, venetoclax, and obinutuzumab as frontline treatment for chronic lymphocytic leukaemia: a single-arm, open-label, phase 2 study

Lancet Oncology, The, 2021
Matthew S Davids, Benjamin L Lampson, Svitlana Tyekucheva   +2 more
exaly  

Obinutuzumab

Case Medical Research, 2016
  +4 more sources

Obinutuzumab

Reactions Weekly, 2015
openaire   +2 more sources

Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial

Lancet Oncology, The, 2020
Othman Al-Sawaf, Anna-Maria Fink, Stephen Opat   +2 more
exaly  

Venetoclax–obinutuzumab combinations are effective in fit patients with CLL

Nature Reviews Clinical Oncology, 2023
exaly  

B-cell depletion with obinutuzumab for the treatment of proliferative lupus nephritis: a randomised, double-blind, placebo-controlled trial

Annals of the Rheumatic Diseases, 2022
Richard A Furie, Brad H Rovin
exaly